Evidence map›Paper›PMID 32193741›Full record

ArticleObesity surgery2020

Gut and Metabolic Hormones Changes After Endoscopic Sleeve Gastroplasty (ESG) Vs. Laparoscopic Sleeve Gastrectomy (LSG).

Gontrand Lopez-Nava, Anuradha Negi, Inmaculada Bautista-Castaño, Miguel Angel Rubio, Ravishankar Asokkumar

4 registry-linked trialsAbstract read
PubMed Publisher
In one paragraph

Article in Obesity surgery, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 4 registered trials, which are not on this map. Cited by 46 papers, 10 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
46citing papers in PubMed, 10 pooled it
9.6field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04306445 naterminatednot on this map

The Effect of a Gas-filled Intragastric Balloon or Endoscopic Sleeve Gastroplasty for Weight Loss Compared With a Meal Replacement Weight Loss Program on Gastric Emptying, Hormonal Adaptation to Weight Loss, and Hunger

TypeinterventionalSponsorUniversity of Colorado, DenverRan2020 to 2024Enrolled3ConditionsObesityArmsGF-IGB: Obalon Balloon, Medically Supervised Meal Replacement Program: My New Weigh, Endoscopic sleeve gastroplasty: (ESG)
NCT05578703 naunknown statusnot on this mapstarted 2022, after this paper: background citation

Gastric Fundus Ablation Plus Endoscopic Sleeve Gastroplasty for Weight Loss

TypeinterventionalSponsorTrue You Weight LossRan2022 to 2026Enrolled10ConditionsObesityArmsFundic Ablation Sequentially in Combination with Endoscopic Sleeve Gastroplasty, Fundic Mucosal Ablation with ERBE HybridAPC, Apollo ESG
NCT05992103 naunknown statusnot on this mapstarted 2023, after this paper: background citation

Single-Stage Gastric Fundus Ablation and Endoscopic Sleeve Gastroplasty for Weight Loss

TypeinterventionalSponsorTrue You Weight LossRan2023 to 2025Enrolled10ConditionsObesityArmsFundic Ablation in Combination with Endoscopic Sleeve Gastroplasty, Fundic Mucosal Ablation with ERBE HybridAPC, Apollo ESG
NCT06420700 recruitingnot on this mapstarted 2024, after this paper: background citation

A Multi-site, Prospective Registry of Patients Undergoing Combined Gastric Mucosal Ablation With Endoscopic Sleeve Gastroplasty at True You Weight Loss

Typeobservational_patient_registrySponsorTrue You Weight LossRan2024 to 2028Enrolled100ConditionsObesityArmsCombined gastric mucosal ablation with endoscopic sleeve gastroplasty
3 · Its place in the literature

Who cites it

46 citing papers in PubMed, 10 syntheses or guidelines pooled it, 74 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Pooled it
  11. Trial
  12. Article
  13. Article
  14. Article
  15. Review
  16. Review
  17. Article
  18. Article
  19. The open accordion: a novel application of endoscopic sleeve gastroplasty for the treatment of refractory gastroparesis.VideoGIE : an official video journal of the American Society for Gastrointestinal Endoscopy · 2024
    Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 2 countries.

Gontrand Lopez-NavaBariatric Endoscopy Unit, HM Sanchinarro University Hospital, Calle de Oña, 28050, Madrid, Spain.
Anuradha NegiBariatric Endoscopy Unit, HM Sanchinarro University Hospital, Calle de Oña, 28050, Madrid, Spain.
Inmaculada Bautista-CastañoBariatric Endoscopy Unit, HM Sanchinarro University Hospital, Calle de Oña, 28050, Madrid, Spain.
Miguel Angel RubioDepartment of Nutrition and Clinical Diabetes, Hospital Clinico San Carlos, Madrid, Spain.
Ravishankar AsokkumarBariatric Endoscopy Unit, HM Sanchinarro University Hospital, Calle de Oña, 28050, Madrid, Spain. ravishnkr03@gmail.com.
Hospital Universitario HM Sanchinarro · ESHospital Clínico San Carlos · ESSingapore General Hospital · SG

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionESG reduces gastric lumen similar to LSG and induces significant weight loss. However, the metabolic and physiological alteration after ESG is not fully understood. We aim to study the gastrointestinal hormone changes after ESG and compared it with LSG.

methodsWe conducted a prospective pilot study comparing ESG and LSG at two centers in Spain. We administered a standard test meal after an overnight fast, and collected blood samples before and after meal. We measured the levels of ghrelin, GLP-1, peptide-YY, insulin, leptin, and adiponectin. We evaluated the hormone profile and weight changes (%TBWL) at baseline and at 6 months after the procedure.

resultsTwenty-four patients were recruited (ESG-12, LSG-12). The baseline age, sex, BMI, and fasting hormone levels were similar between the groups. At 6-month post-ESG, there was a significant decline in the leptin levels. We found a trend towards a decrease in insulin levels and improvement in insulin secretory pattern. We did not observe any change in fasting ghrelin levels, GLP-1, and PYY. At 6 months, LSG induced a significant reduction in the ghrelin, and leptin levels, and increase in peptide-YY, and adiponectin levels, respectively. A trend towards an increase in GLP-1 level was noted. However, no change in insulin was observed. LSG achieved greater %TBWL (24.4 vs. 13.3, p < 0.001) and significantly change in ghrelin, PYY, and adiponectin levels at 6 months compared to ESG.

conclusionESG induced gut hormone changes differently as compared to LSG. ESG prevented a compensatory rise in ghrelin and promoted beneficial changes in the insulin secretory pattern with weight loss.

Indexed as

Gastrointestinal MicrobiomeGastroplastyLaparoscopyObesity, MorbidGastrectomyGhrelinHumansPilot ProjectsProspective StudiesSpainGhrelinESGHormone changesLSGWeight loss

Identifiers

PMID32193741
OpenAlexW3010865687

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.